Hofseth BioCare ASA (0Q6H.L)
| Previous Close | 3.0100 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's Range | 0.0000 - 0.0000 |
| 52 Week Range | |
| Volume | |
| Avg. Volume | 35,386 |
| Market Cap | N/A |
| Beta (5Y Monthly) | 0.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Hofseth Biocare ASA: HBC IMMUNOLOGY COMPLETES IN VIVO DRUG LEAD STUDIES FOR PROSTATE CANCER TREATMENT
Ålesund, Norway, 8 October 2024. HBC Immunology (HBCI) is pleased to announce the successful completion of its prostate cancer treatment xenograft studies with its lead peptide FT-002a in a novel oral formulation in combination with standard of care hormonal-targeting therapy. Oral FT-002a significantly augmented the anti-tumour activity of enzalutamide (Xtandi®) the market-leading androgen receptor inhibitor, in models of indolent and aggressive prostate cancers. Prostate cancer remains the mos
- GlobeNewswire
Hofseth Biocare ASA: SECOND QUARTER AND HALF YEAR 2024 FINANCIAL REPORT
HBC had gross operating revenues of NOK 80.4m (76.4m) in the second quarter and NOK 132.8m (121.2m) for the half year. Adjusted for the sale of assets in the second quarter, sales revenues were NOK 72.2m (50.7m) for the quarter, representing an increase compared to the same quarter in 2023 of 42 percent. Cash and cash equivalents increased by NOK 3.1m during the quarter, leaving total holding at NOK 25.3m at the end of June, compared to NOK 22.4m at the end of March. Including credit facilities,
- GlobeNewswire
Hofseth Biocare ASA: GROUNDBREAKING STUDY REVEALS HOFSETH BIOCARE’S FULL SPECTRUM OMEGAS OMEGO SUPPORTS COVID-19 RECOVERY
Ålesund, Norway, 14 August, 2024 - Hofseth BioCare (HBC), a leader in science-led marine nutrition, proudly announces compelling new findings from a recent study on the benefits of its enzymatically liberated salmon oil, OmeGo®, for COVID-19 recovery. Published in the International Journal of Molecular Sciences, this pioneering research demonstrates that OmeGo® has the potential to improve immune responses and reduce inflammation in individuals with mild to moderate COVID-19 infection, caused by
